Debamestrocel is under clinical development by BrainStorm Cell Therapeutics and currently in the Phase II and Phase III in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Debamestrocel’s likelihood of approval (LoA) and phase transition for Amyotrophic Lateral Sclerosis took place on 08 May 2021, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.

In addition, the same event on 08 May 2021 increased Debamestrocel’s Phase Transition Success Rate (PTSR) for Alzheimer’s Disease, increased LoA and PTSR for Primary Progressive Multiple Sclerosis (PPMS), and increased LoA and PTSR for Secondary Progressive Multiple Sclerosis (SPMS).

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Debamestrocel Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Debamestrocel overview

Debamestrocel (NurOwn) is under development for the treatment of neurodegenerative diseases such as Alzheimer's disease, amyotrophic lateral sclerosis (ALS), progressive multiple sclerosis (primary and secondary sclerosis), Parkinson’s disease (PD), Huntington's disease, peripheral nerve injury, Coronavirus Disease 2019 (COVID-19), acute respiratory distress syndrome and autism spectrum disorder. The therapy is administered by intramuscular and intrathecal routes. NurOwn is an autologous, adult stem cell therapy developed based on a differentiation method which reprograms bone marrow-derived mesenchymal stem cells (MSC) into highly specialized, neuron-supporting cells. It is developed based on NurOwn cell therapy platform.

BrainStorm Cell Therapeutics overview

BrainStorm Cell Therapeutics, formerly Golden Hand Resources Inc, is a biotechnology company which develops autologous stem cell therapies for neurodegenerative diseases. Its pipeline mesenchymal stem cell products are being developed based on cell therapy platform NurOwn, customized for the treatment of multiple sclerosis, amyotrophic lateral sclerosis, parkinson’s disease, huntington’s disease, autism spectrum disorder, peripheral nerve injury and other indications. Its proprietary technology NurOwn induces mesenchymal stem cells to secrete high levels of neurotrophic factors to promote the survival of neurons. The company has operations in the US and Israel. BrainStorm Cell Therapeutics is headquartered in New York, the US.

Quick View Debamestrocel LOA Data

Report Segments
  • Innovator
Drug Name
  • Debamestrocel
Administration Pathway
  • Intramuscular
  • Intrathecal
Therapeutic Areas
  • Central Nervous System
  • Infectious Disease
Key Developers
Highest Development Stage
  • Phase III

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.